Key points are not available for this paper at this time.
Design
Review
Synthesizes hypertension etiology trends; leaves open renewed focus on norepinephrine and renal targets for future trials.
RECENT developments in the study and treatment of essential hypertension, not necessarily progress, represent established trends, not all good, some interesting, and at least one very important. The unanswered problems of etiology remain. A few therapeutic promises are proving most helpful; others are limited or even useless because of annoying or dangerous side effects; still others remain unfulfilled. These trends are as follows:The clinical application of nor-epinephrine raises the blood pressure in a manner so similar physiologically to essential hypertension as to qualify almost as its essence.Interest in the renal origin of essential hypertension, revived twenty years ago . . .
No takes yet. Share an insight, caveat, or question.
Robert S. Palmer (1955) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: